Medically reviewed by Drugs.com. Last updated on Jun 22, 2020.
(me klor ETH a meen)
- Chlorethazine Mustard
- Mechlorethamine Hydrochloride
- Nitrogen Mustard
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution Reconstituted, Injection, as hydrochloride:
Mustargen: 10 mg (1 ea [DSC])
Brand Names: U.S.
- Mustargen [DSC]
- Antineoplastic Agent, Alkylating Agent
- Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)
Mechlorethamine is a bifunctional alkylating agent that inhibits DNA and RNA synthesis via formation of carbonium ions; produces interstrand and intrastrand cross-links in DNA resulting in miscoding, breakage, and failure of replication. Although not cell phase-specific per se, mechlorethamine effect is most pronounced in the S phase, and cell proliferation is arrested in the G2 phase.
Rapid hydrolysis in the plasma to active metabolites (Perry 2012)
15 to 20 minutes (Perry 2012)
Use: Labeled Indications
Hodgkin lymphoma: Palliative treatment of Hodgkin lymphoma
Off Label Uses
Hodgkin lymphoma (previously untreated)
Data from multiple studies support the use of mechlorethamine (in combination with doxorubicin, vinblastine, vincristine, bleomycin, etoposide, prednisone, and radiation therapy [Stanford V regimen]) for management previously untreated Hodgkin lymphoma in patients with either early stage (favorable) or advanced stage (unfavorable) disease [Advani 2013], [Bartlett 1995], [Horning 2000], [Horning 2002].
Hypersensitivity (prior anaphylactic reaction) to mechlorethamine or any component of the formulation; presence of known infectious diseases
Note: Mustargen has been discontinued in the United States for >1 year.
Dosage should be based on ideal dry weight (evaluate the presence of edema or ascites so that dosage is based on actual weight unaugmented by edema/ascites). Mechlorethamine is associated with a high emetic potential (Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting. Dosing in the prescribing information does not reflect current clinical practice.
Hodgkin lymphoma, previously untreated (off-label use/dose): IV:
Stanford V regimen:
Favorable/early stage disease: 6 mg/m2 as a single dose on day 1 every 4 weeks (in combination with doxorubicin, vinblastine, vincristine, bleomycin, etoposide, prednisone, and radiation therapy) for a total of 2 cycles (Advani 2013)
Unfavorable/advanced stage disease: 6 mg/m2 as a single dose on day 1 every 4 weeks (in combination with doxorubicin, vinblastine, vincristine, bleomycin, etoposide, prednisone, and radiation therapy) for a total of 3 cycles (Bartlett 1995; Horning 2000; Horning 2002)
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Refer to adult dosing.
Note: Mustargen has been discontinued in the US for >1 year.
Note: Dosing and frequency may vary by protocol and/or treatment phase; refer to specific protocol. Meclorethamine is associated with a high emetic potential (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2013).
MOPP regimen: Note: The MOPP (with or without ABVD) regimen is generally no longer used due to improved toxicity profiles with other combination regimens used in the treatment of Hodgkin lymphoma (Kelly 2012). Children and Adolescents: IV: 6 mg/m2 on days 1 and 8 of a 28-day cycle in combination with vincristine, procarbazine, and prednisone, may or may not alternate with doxorubicin, bleomycin, vinblastine, dacarbazine (MOPP/ABVD) (Kung 2006; Longo 1986)
Stanford V regimen: Adolescents ≥16 years: IV: 6 mg/m2 as a single dose on day 1 in weeks 1, 5, and 9 (Horning 2000; Horning 2002; Metzger 2012)
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: In general, utilize patient’s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012). Note: The manufacturer recommends dosing be based on ideal dry body weight and the presence of edema or ascites should be considered so the dose will be based on unaugmented weight.
Must be prepared immediately before use; degradation begins shortly after dilution. Reconstitute powder with 10 mL SWFI or NS to a final concentration of 1 mg/mL. Shake vial several times to dissolve completely.
IV: Administer as a slow IV push over a few minutes into a free-flowing IV solution. Mechlorethamine is associated with a high emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting.
Prepare immediately prior to administration.
Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.
Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do NOT flush the line); remove needle/cannula; elevate extremity.
Sodium thiosulfate 1/6 M solution: Inject subcutaneously into extravasation area using 2 mL for each mg of mechlorethamine suspected to have extravasated (Perez Fidalgo 2012; Polovich 2009). Apply ice for 6 to 12 hours after sodium thiosulfate administration (Mustargen prescribing information 2013; Polovich 2009) or may apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (Perez Fidalgo 2012).
Store intact vials at room temperature of 15°C to 30°C (59°F to 86°F). Protect from light. Protect from humidity. Must be prepared immediately before use; degradation begins shortly after dilution.
Baricitinib: Immunosuppressants may enhance the immunosuppressive effect of Baricitinib. Management: Use of baricitinib in combination with potent immunosuppressants such as azathioprine or cyclosporine is not recommended. Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted. Consider therapy modification
BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Monitor therapy
Cladribine: May enhance the immunosuppressive effect of Immunosuppressants. Avoid combination
Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Avoid combination
CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Monitor therapy
Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. Monitor therapy
Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely. Consider therapy modification
Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased. Monitor therapy
Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Avoid combination
Echinacea: May diminish the therapeutic effect of Immunosuppressants. Management: Consider avoiding Echinacea in patients receiving therapeutic immunosuppressants. If coadministered, monitor for reduced efficacy of the immunosuppressant during concomitant use. Consider therapy modification
Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod. Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections). Consider therapy modification
Inebilizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy
Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants. Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly. Consider therapy modification
Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification
Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy. Consider therapy modification
Mesalamine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Avoid combination
Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. Management: Avoid use of immunosuppressants (including systemic corticosteroids) prior to initiation of nivolumab. Use of immunosuppressants after administration of nivolumab (eg, for immune-related toxicity) is unlikely to affect nivolumab efficacy. Consider therapy modification
Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants. Monitor therapy
Ozanimod: Immunosuppressants may enhance the immunosuppressive effect of Ozanimod. Monitor therapy
Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy. Consider therapy modification
Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. Monitor therapy
Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Monitor therapy
Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants. Management: Consider avoiding concomitant use of roflumilast and immunosuppressants as recommended by the Canadian product monograph. Inhaled or short-term corticosteroids are unlikely to be problematic. Consider therapy modification
Siponimod: Immunosuppressants may enhance the immunosuppressive effect of Siponimod. Monitor therapy
Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. Management: Evaluate patients to see if it is medically appropriate to reduce or discontinue therapy with immunosuppressants prior to initiating sipuleucel-T therapy. Consider therapy modification
Smallpox and Monkeypox Vaccine (Live): Immunosuppressants may diminish the therapeutic effect of Smallpox and Monkeypox Vaccine (Live). Monitor therapy
Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants. Avoid combination
Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. Monitor therapy
Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib. Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants. Consider therapy modification
Upadacitinib: Immunosuppressants may enhance the immunosuppressive effect of Upadacitinib. Management: Concomitant use of upadacitinib with potent immunosuppressants is not recommended. Drugs listed as exceptions to this monograph are discussed in separate drug interaction monographs. Avoid combination
Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation. Consider therapy modification
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants. Exceptions: Smallpox and Monkeypox Vaccine (Live). Avoid combination
Frequency not defined.
Cardiovascular: Local thrombophlebitis
Central nervous system: Brain disease (high dose), drowsiness, headache, lethargy, metallic taste, sedation, vertigo
Dermatologic: Alopecia, diaphoresis, erythema multiforme, maculopapular rash, skin rash
Endocrine & metabolic: Amenorrhea, hyperuricemia, oligomenorrhea
Gastrointestinal: Anorexia, diarrhea, mucositis, nausea, vomiting
Genitourinary: Inhibition of spermatogenesis
Hematologic & oncologic: Agranulocytosis, granulocytopenia (onset: 6 to 8 days; recovery: 10 to 21 days), hemolytic anemia, leukopenia, lymphocytopenia, pancytopenia, petechia, thrombocytopenia
Hypersensitivity: Anaphylaxis, hypersensitivity reaction
Infection: Herpes zoster
Neuromuscular & skeletal: Weakness
Otic: Deafness, tinnitus
Miscellaneous: Fever, tissue necrosis (extravasation)
ALERT: U.S. Boxed WarningExperienced physician:
Mechlorethamine injection should be administered only under the supervision of a physician who is experienced in the use of cancer chemotherapeutic agents.Extravasation:
Extravasation of the drug into subcutaneous tissues results in a painful inflammation. The area usually becomes indurated and sloughing may occur. If leakage of drug is obvious, prompt infiltration of the area with sterile isotonic sodium thiosulfate (1/6 molar) and application of an ice compress for 6 to 12 hours may minimize the local reaction. For a 1/6 molar solution of sodium thiosulfate, use 4.14 g of sodium thiosulfate per 100 mL of sterile water for injection or 2.64 g of anhydrous sodium thiosulfate per 100 mL or dilute 4 mL of sodium thiosulfate injection (10%) with 6 mL of sterile water for injection.Hazardous agent:
Mechlorethamine is highly toxic, and both powder and solution must be handled and administered with care. Inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided. Due to the toxic properties of mechlorethamine (eg, corrosivity, carcinogenicity, mutagenicity, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently.
Concerns related to adverse effects:
• Bone marrow suppression: Mechlorethamine may cause hematologic toxicity, including leukopenia, neutropenia, thrombocytopenia, anemia, and lymphopenia. The onsets for neutropenia and thrombocytopenia occur within 6 to 8 days and last for 10 to 21 days. Anemia typically has an onset within 2 weeks and is generally mild. The lymphocytopenia onset occurs within 1 day. Agranulocytopenia or hemolytic anemia may rarely occur. Severe hematologic toxicity may occur in patients with widespread disease, poor performance status, and/or those previously treated with other antineoplastic agents or radiation therapy. Bone marrow suppression may be prolonged (up to 50 days or longer); persistent pancytopenia has also been reported. Monitor blood counts. Bleeding due to severe thrombocytopenia may occur. Use with caution in patients with preexisting leukopenia, thrombocytopenia, and anemia or with tumor invasion of the bone marrow; treatment response (as defined by the absence of tumor in the bone marrow) may be associated with improvement of bone marrow function. However, in nonresponders or heavily pretreated patients, hematopoietic function may be further compromised, leading to more severe (and potentially fatal) leukopenia, thrombocytopenia, and anemia. Bone marrow function should recover after mechlorethamine administration prior to initiating radiation therapy or other chemotherapy regimens.
• Extravasation: Mechlorethamine is a vesicant. [US Boxed Warning]: Extravasation results in painful inflammation with induration and sloughing. If extravasation occurs, promptly manage by infiltrating area with 1/6 molar sodium thiosulfate solution, followed by dry cold compresses for 6 to 12 hours to minimize the reaction. For a 1/6 molar solution of sodium thiosulfate, use 4.14 g of sodium thiosulfate per 100 mL of sterile water for injection or 2.64 g of anhydrous sodium thiosulfate per 100 mL or dilute 4 mL of sodium thiosulfate injection (10%) with 6 mL of sterile water for injection. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.
• Gastrointestinal toxicities: Mechlorethamine is associated with a high emetic potential (Dupuis 2011; Hesketh 2017; Roila 2016); antiemetics are recommended to prevent nausea and vomiting. Nausea may persist for up to 24 hours.
• Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, have been reported.
• Immunosuppression: Mechlorethamine has immunosuppressant properties. May predispose patients to infections (bacterial, viral, or fungal).
• Secondary malignancies: Alkylating agents, including mechlorethamine, are associated with an increased incidence of secondary malignancies; concurrent radiation therapy or combination chemotherapy may increase the risk.
• Tumor lysis syndrome: Hyperuricemia may occur, especially with lymphomas; ensure adequate hydration; consider antihyperuricemic therapy if appropriate.
• Amyloidosis: Nitrogen mustards may contribute to extensive/rapid development of amyloidosis. Mechlorethamine should only be used if foci of suppurative inflammation (acute and chronic) are absent.
• Nonresponding tumors: Bone and nervous system tumors typically respond poorly to mechlorethamine. The routine use of mechlorethamine in widely disseminated tumors is discouraged.
• Hazardous agent: [US Boxed Warning]: Mechlorethamine is a highly toxic nitrogen mustard; avoid inhalation of vapors or dust; avoid dust or vapor contact with skin or eyes; review and follow special handling procedures. If accidental skin exposure occurs, wash/irrigate thoroughly with water for at least 15 minutes, followed by 2% sodium thiosulfate solution; remove and destroy any contaminated clothing. If exposure to eye(s) occurs, promptly irrigate for at least 15 minutes with copious amounts of water, normal saline, or balanced salt ophthalmic irrigating solution; obtain ophthalmology consultation. The manufacturer recommends neutralizing remaining unused mechlorethamine, empty or partial vials, gloves, tubing, glassware, etc., after mechlorethamine administration; soak in an aqueous solution containing equal volumes of sodium thiosulfate (5%) and sodium bicarbonate (5%) for 45 minutes; rinse with water; dispose of properly.
• Experienced physician: [US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.
• Topical application: A gel formulation is commercially approved for topical treatment of cutaneous T-cell lymphoma (mycosis fungoides-type); refer to Mechlorethamine (Topical) monograph.
CBC with differential and platelet count; renal and hepatic function. Monitor for signs/symptoms of hypersensitivity reactions and infection. Monitor infusion site for extravasation.
Females of reproductive potential are advised not to become pregnant during mechlorethamine treatment.
Delayed menses, oligomenorrhea, or temporary or permanent amenorrhea may be observed in female patients treated with mechlorethamine. Impaired spermatogenesis, azoospermia, and total germinal aplasia may occur in male patients treated with mechlorethamine, particularly when used in combination with other chemotherapy agents.
Pregnancy Risk Factor
[US Boxed Warning]: Mechlorethamine is highly toxic, and both powder and solution must be handled and administered with care. Inhalation of dust or vapors and contact with skin or mucous membranes, especially those of the eyes, must be avoided. Avoid exposure during pregnancy. Due to the toxic properties of mechlorethamine (eg, teratogenicity), special handling procedures should be reviewed prior to handling and followed diligently.
Mechlorethamine may cause fetal harm if administered to a pregnant female.
What is this drug used for?
• It is used to treat cancer.
• It may be given to you for other reasons. Talk with the doctor.
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Lack of appetite
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Bleeding like vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe or persistent bleeding
• Severe loss of strength and energy
• Severe injection site redness, burning, swelling, pain, or irritation
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about mechlorethamine
Other brands: Mustargen